Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT02367313 is registered in ClinicalTrials.gov with Biota Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02367313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02367313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Lead sponsor
Biota Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2015
Completion date
December 31, 2016
Enrollment
455 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

asthma